Login / Signup

Comparison of Bayesian and frequentist monitoring boundaries motivated by the Multiplatform Randomized Clinical Trial.

Jungnam JooEric S LeiferMichael A ProschanJames F TroendleHarmony R ReynoldsErinn A HadePatrick R LawlerDong-Yun KimNancy L Geller
Published in: Clinical trials (London, England) (2024)
In a pandemic where quickly weeding out ineffective treatments and identifying effective treatments is paramount, aggressive monitoring may be preferred to conservative approaches, such as the O'Brien-Fleming boundary. This can be accomplished with either Bayesian or frequentist methods.
Keyphrases
  • sars cov
  • coronavirus disease
  • clinical trial
  • double blind